Hypofractionated Preoperative Radiation for Head and Neck Cancers (HyPR-HN)

Head and Neck Cancer Clinical Trial

Official title:

A Phase I Study of Hypofractionated Preoperative Radiation for Head and Neck Cancers (HyPR-HN)

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT05538533
• Other study ID #: PRO44863
• Status: Recruiting
• Phase: N/A
• Start date: January 6, 2023
• Est. completion date: December 2026

Study information

• Verified date: March 2024
• Source: Medical College of Wisconsin
• Contact: Medical College of Wisconsin Cancer Center Clinical Trials Offic
• Phone: 866-680-0505
• Email: cccto[@]mcw.edu
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This is a phase 1 study to determine the safety of a condensed preoperative radiation regimen (10, 7, or 5 fractions) for the management of head and neck squamous cell carcinoma.

Description:

All subjects in this study will receive hypofractionated adjuvant radiation therapy, which will be subject to fractionation reduction, that being 10 fractions, 7 fractions, or 5 fractions, as compared to 30 fractions of conventional radiation therapy.

The subjects will receive smaller number of fractions (total visits) but with a higher dose of radiation. Participants will receive a total radiation dose of 46 Gy in 10 fractions (Dose Level 1), 40 Gy in 7 fractions (Dose Level 2), or 35 Gy in 5 fractions (Dose Level 3), depending on the assigned experimental total fractions. Radiation will be delivered using intensity modulated radiation therapy (IMRT) with a daily cone-beam CT for five days a week, for less than two weeks depending on the assigned dose level at the time of enrollment.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 18
• Est. completion date: December 2026
• Est. primary completion date: August 2026
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

1. Patients 18 years or older with surgically resectable, Human papillomavirus (HPV) -negative squamous cell carcinoma of the head and neck (squamous cell carcinoma of the larynx, hypopharynx, oropharynx, oral cavity, nasal cavity or paranasal sinuses). Resectability will be determined by the treating surgeon. Patients must have locoregionally advanced disease defined by clinical T3-4 staging and/or clinical node positive staging. Patients may also be eligible if they meet one of the following criteria:

1. Clinical T2N0 disease with perineural invasion identified on a pretreatment biopsy.

2. Clinical T2N0 disease with lymphovascular space invasion identified on a pretreatment biopsy.

3. Clinical T2N0 oral cavity cancer with clinical, biopsy, or radiographic depth of invasion of at least 5 mm.

2. Zubrod performance status 0-2.

3. Patients must have the psychological ability and general health that permits completion of the study requirements and required follow-up.

4. Inclusion of COVID-19 positive patients will be based on standard institutional protocol.

5. Female patients must meet one of the following:

• Postmenopausal for at least one year before the screening visit, OR

• Surgically sterile (i.e., undergone a hysterectomy or bilateral oophorectomy), OR

• If subject is of childbearing potential (defined as not satisfying either of the above two criteria), agrees to practice two acceptable methods of contraception (combination methods require use of two of the following: diaphragm with spermicide, cervical cap with spermicide, contraceptive sponge, male or female condom, hormonal contraceptive) from the time of signing of the informed consent form through 90 days after the last dose of study agent, AND

• Agrees to practice true abstinence when this is in line with the preferred and usual lifestyle of the subject. (Periodic abstinence [e.g., calendar, ovulation, symptom-thermal, postovulation methods] and withdrawal are not acceptable contraception methods).

6. Male patients, even if surgically sterilized (i.e., status post vasectomy), must agree to one of the following:

• Practice effective barrier contraception during the entire study period and through 60 calendar days after the last dose of study agent, OR

• Must also adhere to the guidelines of any study-specific pregnancy prevention program, if applicable, OR

• Agree to practice true abstinence when this is in line with the preferred and usual lifestyle of the subject. (Periodic abstinence [e.g., calendar, ovulation, symptom-thermal, postovulation methods] and withdrawal are not acceptable methods of contraception.

7. Ability to understand a written informed consent document, and the willingness to sign it.

Exclusion Criteria:

1. Radiographic evidence of extranodal extension.

2. Patients with laryngeal involvement who are candidates for non-surgical laryngeal preservation as deemed by a surgeon and/or radiation oncologist. These patients include, but are not limited to, those with T1-T3 laryngeal cancer who do not have pretreatment tracheostomy and/or feeding tube or those with base of tongue/hypopharyngeal cancers with laryngeal involvement without cartilage invasion or pretreatment tracheostomy and/or feeding tube.

3. HPV-positive squamous cell carcinoma.

4. Prior invasive malignancy within the past three years (except for non-melanomatous skin cancer, and early stage treated prostate cancer).

5. Life expectancy less than 12 months.

6. Zubrod performance status = 3.

7. Patients with prior radiation therapy to the head and neck (Note: Prior external beam radiotherapy is excluded, but iodine-131 is allowed).

8. Prior systemic therapy, including cytotoxic chemotherapy, biologic/targeted therapy, or immune therapy for the study cancer.

9. Body weight = 30 kg.

10. Any of the following severe laboratory abnormalities within 14 days of registration, unless corrected prior to it: sodium < 130 mmol/L or > 155 mmol/L; potassium < 3.5 mmol/L or > 6 mmol/L; fasting glucose < 40 mg/dL or > 400 mg/dL; serum calcium (ionized or adjusted for albumin) < 7 mg/dL or > 12.5 mg/dL; magnesium < 0.9 mg/dL or > 3 mg/dL.

11. Unstable angina and/or congestive heart failure requiring hospitalization within three months prior to step 1 registration.

12. Transmural myocardial infarction within three months prior to step 1 registration.

13. Medical or psychiatric illness which would compromise the patient's ability to tolerate treatment or limit compliance with study requirements.

14. Pregnancy or women of childbearing potential and men who are sexually active and not willing/able to use medically acceptable forms of contraception during treatment and for six months after radiation, this exclusion is necessary because the treatment involved in this study may be significantly teratogenic. Women who are breastfeeding are also excluded.

Related Conditions & MeSH terms

• Head and Neck Cancer
• Head and Neck Neoplasms

Intervention

Radiation:
• 46 Gy Radiation Therapy
Dose per fraction of 4.6.
• 40 Gy Radiation Therapy
Dose per fraction 5.7.
• 35 Gy Radiation Therapy
Dose per fraction 7.0.

Locations

Country	Name	City	State
United States	Froedtert Hospital and the Medical College of Wisconsin	Milwaukee	Wisconsin

Sponsors (1)

Lead Sponsor	Collaborator
Medical College of Wisconsin

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	The number of subjects with a dose-limiting toxicity related to inoperability.	Inoperability after HyPR-HN, is defined as an inability to proceed to surgery within eight weeks of radiation.	8 Weeks
Primary	The number of subjects with a dose-limiting toxicity related to perioperative complication rates.	Severe perioperative complication rates, defined as unacceptable toxicity from initiation of treatment until 30 days postoperatively (grade 4/5 toxicity) probably or definitely related to treatment.	8 Weeks
Primary	The number of subjects with severe delayed toxicity.	Severe delayed toxicities, defined as any unacceptable toxicity (grade 4+) after 30 days postoperatively until one year after initiation of HyPR-HN probably or definitely related to treatment.	Up to one year
Secondary	Overall survival	This measure is the number of subjects alive at one year following the conclusion of scheduled radiation therapy.	One year
Secondary	Recurrence-free Survival	This measure is the number of subjects who are survival free of locoregional recurrence or distant metastasis.	One year